Dublin/Oxford biopharma developing emactuzumab for tenosynovial giant cell tumour.
| Date | Round | Amount |
|---|---|---|
| Apr 2024 | Series B SynOx Therapeutics secured $75m in Series B financing co-led by Forbion, HealthCap and Bioqube Ventures to run a phase 3 trial of emactuzumab for TGCT. | $75M |